Cenvacibart

塞瓦西拜单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameCenvacibart
Drug Alias NameREGN7508
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoagulation factor XI inhibitors
TargetsCoagulation factor XI
Therapy Area/IndicationsThrombosisVenous ThromboembolismPeripheral Arterial Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsThrombosisVenous ThromboembolismPeripheral Arterial Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A